Comparative Pharmacology
Head-to-head clinical analysis: NERATINIB MALEATE versus NINTEDANIB ESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NERATINIB MALEATE versus NINTEDANIB ESYLATE.
NERATINIB MALEATE vs NINTEDANIB ESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversible inhibitor of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) tyrosine kinases, leading to inhibition of downstream signaling pathways and tumor cell proliferation.
Nintedanib esylate is a tyrosine kinase inhibitor that binds competitively to the ATP-binding pocket of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-α, PDGFR-β), and fibroblast growth factor receptors (FGFR-1, FGFR-2, FGFR-3). This inhibition blocks downstream signaling pathways involved in angiogenesis and fibrosis.
240 mg (6 tablets of 40 mg) orally once daily with food, continuously until disease progression or unacceptable toxicity.
150 mg orally twice daily, 12 hours apart, taken with food.
None Documented
None Documented
Terminal half-life is approximately 7–17 hours (mean 12 hours); this supports twice-daily dosing. Steady-state is achieved within 7 days.
Terminal elimination half-life is approximately 10 hours in patients with IPF; steady state reached within 7 days.
Primarily fecal (approximately 97% of the administered dose recovered in feces as unchanged drug and metabolites); renal excretion is minimal (approximately 1% of the dose recovered in urine).
Biliary/fecal: >90% (unchanged and metabolites); Renal: <1%
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor